glp-1 drug updates How medications are transforming diabetes and weight loss treatment GLP-1 Drugs: 2025 Pulse Survey

One key group includes individuals who arent looking for weight loss but want to support their metabolic health, manage chronic inflammation, or take a proactive approach to disease prevention and longevity

Semaglutide at doses of 0.5 and 1.0 mg once weekly (Ozempic, Novo Nordisk) has been approved for the treatment of T2DM and has been marketed since 2018 (Figure 8)

Yet the individuals most affected by obesity and metabolic dysfunction are disproportionately those with lower incomes and less access to comprehensive health insurance coverage

Katsila T., Spyroulias G

[DOI] [PMC free article] [PubMed] [Google Scholar] 3.Khalaf RA, et al

These risks are compounded in a landscape where pharmacies are under pressure to meet rising demand, reduce delivery timeframes, and ensure absolute compliance